China biotech outlicensing tops US$52 billion in first 2 months after global deal surge
South China Morning Post
by Julie ZhangMarch 4, 2026
The pace and size of outlicensing deals between Chinese drug makers and global partners have accelerated this year, highlighted by two agreements announced this week, each worth more than US$1 billion.
The string of deals shows how China is becoming a sought-after source of drug candidates for multinational pharmaceutical companies, which are increasingly looking for long-term partnerships rather than one-off arrangements, analysts said.
The latest deals, Sino Biopharmaceutical’s agreement with...
Verticals
worldasia
Originally published on South China Morning Post on 3/4/2026